Takeda engaged in antitrust scheme to delay generic constipation drug: U.S. jury
Takeda engaged in antitrust scheme to delay generic constipation drug: U.S
The Japan Times
Verify original report
Hero image carried from the source feed. Verify imagery and captioning at The Japan Times.
The readable version, with the source trail intact.
This page turns the linked publisher report into a plain-English briefing, while keeping the original article and image trail easy to check.
The useful update
- Takeda engaged in antitrust scheme to delay generic constipation drug: U.S
- The verdict is the first time a jury has found a pharmaceutical company liable in class-action litigation over what is called a
The stakes
- Federal antitrust law that covers the bulk of the plaintiffs’ claims allows damages to be automatically tripled, meaning $821.7 million of the jury’s award could swell to $2.47 billion
- Your subscription plan doesn't allow commenting
The next check
- If the story affects a decision, open the original The Japan Times report and the relevant official page before relying on local prices or timing
Where this came from
-
01
Original report Takeda engaged in antitrust scheme to delay generic constipation drug: U.S. jury
Publisher: The Japan Times · Published May 19, 6:51 am · japantimes.co.jp
Open original -
02
TortoisePath layer TortoisePath Story Breakdown
Summary generated 3 months ago from the original report.
-
03
Visual trail 2 attributed source images
Image cards below keep the publisher attribution and link back to the original article.
Jump to images
The short version
The verdict is the first time a jury has found a pharmaceutical company liable in class-action litigation over what is called a
BOSTON – A U.S. jury on Monday found Japan-based Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an anticompetitive scheme. Jurors in federal court in Boston, following a five-wee…
The award could rise to several billion dollars. Federal antitrust law that covers the bulk of the plaintiffs’ claims allows damages to be automatically tripled, meaning $821.7 million of the jury’s award could swell to $2.47 billion
What happened
- Takeda engaged in antitrust scheme to delay generic constipation drug: U.S
- The verdict is the first time a jury has found a pharmaceutical company liable in class-action litigation over what is called a
- jury on Monday found Japan-based Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an anticompetitive scheme
- Jurors in federal court in Boston, following a five-week trial, sided with wholesalers, insurers, health funds and retailers including CVS and Walgreens, who said the delay forced them to overpay for the drug
- The award could rise to several billion dollars
Why this matters
- Federal antitrust law that covers the bulk of the plaintiffs’ claims allows damages to be automatically tripled, meaning $821.7 million of the jury’s award could swell to $2.47 billion
- Your subscription plan doesn't allow commenting
- The practical value is the source trail: The Japan Times is the place to check before acting on prices, dates, availability, or local implications
Open these next
Images published alongside the source story
Each image keeps its publisher, caption or article title, citation text, and a direct path back to the original article for verification.
The Japan Times
Image from The Japan Times via the original article.
The Japan Times
Original articleTakeda engaged in antitrust scheme to delay generic constipation drug: U.S. jury
Image from The Japan Times via the original article.